ADAPY · Adaptimmune Therapeutics PLC · Analyst Estimates
$0.03
-0.01 (-18.92%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2025
Substantial doubt about the company's ability to continue as a going concern.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Aug 13, 2025
Market Cap
$31.81M
Shares
1.59B
Volume · Oct 5
234.5K
Avg daily vol (3M)
243.49K
Analyst Estimates
Compare analyst forecasts for Adaptimmune Therapeutics PLC across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 07:40 UTC · Publication dates shown per estimate · 4 metric / period groups
FY ending 2025-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
Q ending 2025-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|